2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Genomics, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

247 Phase 1/2 study of azacitidine plus quizartinib in patients with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms

Roberta S. Santos Azevedo, MD, Kelly Sharon Chien, MD2, Elias Jabbour, MD3, Nitin Jain, MD4, Abhishek Maiti, MBBS5, Courtney DiNardo, MD, MSCE6, Gautam Borthakur, MD7, Danielle Hammond, MD8, Fadi G. Haddad, MD9, Maro Ohanian, DO10, Koichi Takahashi, MD,PhD11, Lucia Masarova, MD12, Nicholas Short, MD13, Wei Ying Jen, BM BCh, FRCPath14, Sanam Loghavi, MD15, Xuelin Huang, PhD16, Stephany Hendrickson17, Heather Schneider, BSN, RN18, Naval Daver, MD19, Guillermo Garcia-Manero, MD20, Guillermo Montalban-Bravo, MD21
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Kinase signaling activation is a known mechanism of progression and treatment resistance in myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MDS/MPNs). We previously reported results from the phase 1 portion of this study, demonstrating the safety of azacitidine (AZA) plus quizartinib (QUIZ) in patients (pts) with FLT3- or CBL-mutated MDS or MDS/MPN and establishing the recommended phase 2 dose (RP2D) (Montalban-Bravo G et.al, Leukemia Research, 2024). Here, we report results from the phase 2 portion and updated outcomes for the overall study population.

Methods: This phase 1/2 study enrolled pts with MDS or MDS/MPN harboring FLT3 or CBL mutations. Inclusion of other FLT3 wildtype pts was allowed in a later amendment. Pts received AZA 75 mg/m² IV/SC on days 1–5 and oral QUIZ daily on days 1–28 of each cycle. The phase 1 portion evaluated 3 QUIZ dose levels: 30 mg (n=3), 40 mg (n=3), and 60 mg (n=6). QUIZ 40 mg was selected as the RP2D. The primary endpoint of the phase 2 portion was overall response rate (ORR), defined as complete remission (CR), partial remission (PR), marrow CR (mCR), or hematologic improvement (HI). Secondary endpoints included leukemia-free survival (LFS), overall survival (OS), and safety. Efficacy and outcome analyses included all pts enrolled in both phases of the study.

Results: From July 2020 to April 2026, 30 pts were enrolled. Median age was 73 years (range, 57–83). 16 pts (54%) had chronic myelomonocytic leukemia (CMML), 10 (33%) had MDS, 3 (10%) had MDS/MPN with neutrophilia, and 1 (3%) had MDS/MPN-NOS. 6 pts (20%) had experienced HMA failure. Median bone marrow (BM) blast percentage at enrollment was 8% (range, 1–18). According to IPSS-M, 6 pts (20%) had high risk and 15 (50%) had very high-risk disease. Among CMML pts, 9 had myeloproliferative subtype and 1 (6%), 5 (31%), and 10 (63%) had intermediate-1, intermediate-2, and high-risk disease by CPSS-Mol, respectively. 11 pts (37%) had FLT3-ITD, and 14 (47%) had CBL mutations.

By 2006 International Working Group (IWG) criteria, the ORR was 60% (18/30), including CR in 10%, mCR with HI in 10%, mCR in 33%, and HI in 7%. The ORR was 73% among FLT3-ITD mutant pts and 43% among CBL mutant pts. The ORR was 59% for HMA-naïve pts and 50% for those with prior HMA failure. By 2023 IWG criteria, the ORR was 67% (20/30), including CR in 20%, CR equivalent in 17%, and CR with limited count recovery (CRL) in 30%. Median number of cycles to best response was 2 (range, 1–6).

At data cutoff, pts had received a median of 5 cycles (range, 1–17). 25 pts (83%) had discontinued study treatment. Main reasons for discontinuation included hematopoietic stem cell transplantation (n=10), transformation to acute myeloid leukemia (n=5), relapse (n=2), and toxicity (n=2). At a median follow-up of 39 months (95% CI, 20–NR), the median LFS was 16 months (95% CI, 14–NR), and the median OS was 22 months (95% CI, 15–NR). Among pts with FLT3-ITD, the median LFS and OS were 28 months (95% CI, 19–NR) and 29 months (95% CI, 27–NR), respectively. Among pts with CBL mutations, the median LFS was 14 months (95% CI, 6–NR), and the median OS was 19 months (95% CI, 11–NR).

The most common grade ≥3 adverse events were thrombocytopenia (40%), anemia (27%), febrile neutropenia (7%), QTc prolongation (7%), neutropenia (7%), hyponatremia (7%), lung infection (7%), skin infection (7%), and sepsis (7%). Both pts who experienced QTc prolongation discontinued study treatment because of toxicity. The 30- and 60-day mortality rates were 0%. The median cycle 1 duration was 32 days (range, 28–57). Among pts receiving >1 cycle, the median time to absolute neutrophil count recovery to ≥1 × 10?/L and platelet count recovery to ≥50 × 10?/L were 26 and 27 days, respectively. Among the 24 pts who received ≥2 cycles of therapy, 10 (42%) required a reduction in either the dose or the number of treatment days: 3 (13%) required a reduction in azacitidine alone, 3 (13%) in quizartinib alone, and 4 (16%) in both agents.

Single-cell RNA sequencing and cytometry by time of flight (CyTOF) of BM mononuclear cells to evaluate the effects of therapy in BM cell populations is underway and will be presented at the meeting.

Conclusion: AZA plus QUIZ showed encouraging activity in high-risk MDS or MDS/MPN, with responses also observed among those with prior HMA failure. The combination continued to demonstrate safety profile consistent with the known profile with longer follow-up.
Guillermo Montalban-Bravo, MD: Solu Therapeutics - Research Funding; Rigel Pharmaceuticals - Research Funding; Takeda Oncology - Research Funding